- Home
- PNI vs CELU Comparison
PNI vs CELU Comparison
Compare PNI & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- CELU
- Stock Information
- Founded
- PNI 2002
- CELU 2016
- Country
- PNI United States
- CELU United States
- Employees
- PNI N/A
- CELU N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- CELU Health Care
- Exchange
- PNI Nasdaq
- CELU Nasdaq
- Market Cap
- PNI 77.2M
- CELU 64.3M
- IPO Year
- PNI N/A
- CELU N/A
- Fundamental
- Price
- PNI $6.95
- CELU $2.15
- Analyst Decision
- PNI
- CELU Strong Buy
- Analyst Count
- PNI 0
- CELU 1
- Target Price
- PNI N/A
- CELU $6.00
- AVG Volume (30 Days)
- PNI 26.4K
- CELU 136.2K
- Earning Date
- PNI 01-01-0001
- CELU 08-29-2025
- Dividend Yield
- PNI 4.76%
- CELU N/A
- EPS Growth
- PNI N/A
- CELU N/A
- EPS
- PNI N/A
- CELU N/A
- Revenue
- PNI N/A
- CELU $44,590,000.00
- Revenue This Year
- PNI N/A
- CELU N/A
- Revenue Next Year
- PNI N/A
- CELU $76.00
- P/E Ratio
- PNI N/A
- CELU N/A
- Revenue Growth
- PNI N/A
- CELU 4.45
- 52 Week Low
- PNI $6.03
- CELU $1.00
- 52 Week High
- PNI $7.89
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- PNI 73.75
- CELU 34.61
- Support Level
- PNI $6.49
- CELU $2.05
- Resistance Level
- PNI $6.93
- CELU $2.41
- Average True Range (ATR)
- PNI 0.07
- CELU 0.30
- MACD
- PNI 0.03
- CELU -0.10
- Stochastic Oscillator
- PNI 90.49
- CELU 6.57
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.